<DOC>
	<DOC>NCT01359293</DOC>
	<brief_summary>The primary objective of this study is to compare the effects of paliperidone versus oral antipsychotics on changes in brain parenchymal volume, number of relapses, and time to relapse during a one-year period of follow up of patients with new onset schizophrenia.</brief_summary>
	<brief_title>Effects of Paliperidone Palmitate Versus Oral Antipsychotics on Clinical Outcomes and MRI Measures</brief_title>
	<detailed_description>Subjects will participate in 1 year of treatment with 3 MRI scans at six month intervals. Side effects and metabolic measures will be followed over the course of the study.</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>1. Patients with a DSMIV diagnosis of schizophrenia or schizophreniform disorder 2. Age range 1840 3. Ability to provide informed consent 4. First episode (first hospital admission) or recent onset (no more than five years since onset of first psychotic symptom) 1. Substance dependence either currently or during the month prior to entry (except caffeine and nicotine) 2. Unstable medical conditions 3. Pregnant or lactating women 4. Implanted pacemaker, medication pump, vagal stimulator, deep brain stimulator, TENS unit, or ventriculoperitoneal shunt (because of MR studies). 5. IQ less than 70</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>